Press releases

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company whose mission is to develop new treatments for unmet medical needs in the field of cardiovascular disease, today announced the issuance of a key new patent by the European Patent Office.
 

This patent (N° 2 793 878), for which an international application was filed in December 2012, protects the therapeutic use of drug candidate QGC001 in combination with multiple medications approved and widely prescribed for the treatment of high blood pressure or heart failure. It is valid until 2032 and has been filed in the 37 member states of the European Patent Organization. 
 

Specifically, it protects all pharmaceutical compositions combining the QGC001 product with the following angiotensin converting enzyme inhibitors: enalapril (Renitec®, Vasotec®), ramipril (Triatec®, Altace®), captopril (Lopril®, Capoten®), and quinapril (Acuitel®, Accupril®), as well as combinations with valsartan (Tareg®, Diovan®), losartan (Cozaar®), olmesartan (Alteis®, Benicar®) and candesartan (Atacand®, Kenzen®), which are angiotensin II receptor blockers. 
 

"The issuance of this patent by the European office is yet another acknowledgement of the novelty and inventiveness of our therapeutic approach, which is based on the inhibition of aminopeptidase A activity in the brain. 
 

Within the framework of our QGC011combination program, we have succeeded in demonstrating in animals the synergistic action of our product (QGC001) with enalapril, and to a lesser extent with valsartan and losartan, which collectively suggest that pharmaceutical compounds combining our drug candidate with these active ingredients could provide a more effective and better tolerated treatment for patients suffering from high blood pressure or chronic heart failure.” 
 

 

ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.
The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC). 
The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com. 
 

CONTACTS

Quantum Genomics
Lionel Ségard
Chairman & Chief Executive Officer
+33 1 85 34 77 77

Quantum Genomics
Marc Karako
CFO – Investor Relations
+33 1 85 34 77 75
[email protected]

ACTUS finance & communication (Europe)
Jean-Michel Marmillon
Press Relations
+33 1 53 67 36 73 / [email protected]

The Ruth Group (U.S.)
Lee Roth / Kirsten Thomas
Investor / Public Relations
+1 646-536-7012 / +1 508-280-6592